Ryan Hoang, Mary E Acosta, Mark N Belkin, Nabeel F Rasheed, Umar Siddiqi, Jennifer M Cruz, Sydney E Lupo, Corinne R Stonebraker, Sara Kalantari, Jonathan Grinstein
We assessed the prognostic potential of Galectin-3 in a sample of 159 heart failure patients who received a left ventricular assist device (LVAD) implant from 2012 to 2020. Clinical outcomes included hemodynamic data, right heart failure (RHF), hemocompatibility-related adverse events (HRAEs), and mortality. Galectin-3 was compounded into Michigan-RVF and EUROMACS-RHF risk scores and compared to the noncompounded risk scores. Right heart failure was significantly correlated with Galectin (p = 0.004) on a continuous spectrum...
August 2, 2024: ASAIO Journal: a Peer-reviewed Journal of the American Society for Artificial Internal Organs